If you would, tell us what your company does and let's talk about your lead product, which is the Gelrin C. Let's learn a little bit more about your company and what you do for your patients.

Okay.

So thank you for your question and the time.

Our company, Regentis, is called that way because we are focused on developing technologies for regeneration of tissue, hence the name.

Regeneration of tissue, when you are able to match the therapy the ailment with the technology in tissue regeneration, you probably have the best medicine possible because otherwise you're resorting to chemicals, drugs, devices, and so on.

In our particular case, we have a platform from which we can develop a variety of applications.

But currently we are focused, our lead product is called Gelrin C, GELWIN is the platform, and C stands for cartilage.

So from an investor standpoint, looking at the next 12 to 18 months, if you will, what are some of the catalysts you want investors, interested parties to be looking out for?

If you would, tell us what your company does and let's talk about your lead product, which is the Gelrin C. Let's learn a little bit more about your company and what you do for your patients.

Okay.

So thank you for your question and the time.

Our company, Regentis, is called that way because we are focused on developing technologies for regeneration of tissue, hence the name.

Regeneration of tissue, when you are able to match the therapy the ailment with the technology in tissue regeneration, you probably have the best medicine possible because otherwise you're resorting to chemicals, drugs, devices, and so on.

In our particular case, we have a platform from which we can develop a variety of applications.

But currently we are focused, our lead product is called Gelrin C, GELWIN is the platform, and C stands for cartilage.

So from an investor standpoint, looking at the next 12 to 18 months, if you will, what are some of the catalysts you want investors, interested parties to be looking out for?